Hyderabad-based Natco Pharma Limited has signed a pact with Dr Reddy's Laboratories Limited for the development, manufacture and supply of a basket of value-added generic oncology drugs. Dr Reddy's and Natco would together develop these products for registration and commercialization across the globe including markets of US and EU. Natco will exclusively supply the products to Dr Reddy's.

 

The products selected under this agreement include currently selling oral and injectable innovator products. These products have multi-million dollar sales across the globe. One of the products is Paclitaxel, which is a generic version of Abraxane. According to the deal, Dr Reddy's would pay an undisclosed amount as upfront to Natco for securing rights to the product portfolio and capacity required to manufacture products.

 

Under the agreement, Dr Reddy's would have exclusive commercialization rights for certain products worldwide. It would also have territory specific commercialization rights for all other products, including the US and EU. Apart from this, both parties have a profit sharing mechanism in their respective designated territories.